Lucius LuciVeric Vericiguat 10mg

Product Information

• Product name: LuciVeric Vericiguat10 mg98 Vericiguat 10mg
• Manufacturer / brand: Laos Lucius Pharma
• Active ingredient: Vericiguat
• Current strength: 10mg
• SKU: Product ID 3113
• Site category: general medicines

Product Summary

LuciVeric Vericiguat10 mg98 Vericiguat 10mg is an AISTIKA-listed product supplied by Laos Lucius Pharma. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Vericiguat is the active ingredient used for this product page. Public prescribing information for Vericiguat was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

Vericiguat is a stimulator of soluble guanylate cyclase (sGC), an important enzyme in the nitric oxide (NO) signaling pathway. When NO binds to sGC, the enzyme catalyzes the synthesis of intracellular cyclic guanosine monophosphate (cGMP), a second messenger that plays a role in the regulation of vascular tone, cardiac contractility, and cardiac remodeling. Heart failure is associated with impaired synthesis of NO and decreased activity of sGC, which may contribute to myocardial and vascular dysfunction.

Reference Indications

Vericiguat ® is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45% . Vericiguat is a soluble guanylate cyclase (sGC) stimulator, indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.

Reference Dosage and Administration

Swallow whole tablets.

Dose conversion must be confirmed by a physician because the reference dose may vary by indication, organ function, toxicity, or interacting medicines.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

WARNING: EMBRYO-FETAL TOXICITY Females of reproductive potential: Exclude pregnancy before the start of treatment. Do not administer Vericiguat to a pregnant female because it may cause fetal harm . WARNING: EMBRYO-FETAL TOXICITY See for complete boxed warning. Do not administer Vericiguat to a pregnant female because it may cause fetal harm. ( 4 , 5.1 , 8.1 ) Females of reproductive potential: Exclude pregnancy before the start of treatment. ( 2.2 , 5.1 , 8.3 ) 5.1 Embryo-Fetal Toxicity Based on data from animal reproduction studies, Vericiguat may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus. Obtain a pregnancy test before the start of treatment.

Common Adverse Reactions and Monitoring

Vericiguat was evaluated in VICTORIA, which included 2,519 patients treated with Vericiguat (up to 10 mg once daily). The mean duration of Vericiguat exposure was 1 year, and the maximum duration was 2.6 years . Table 1 lists adverse drug reactions occurring more commonly with Vericiguat than placebo and in ≥5% of patients treated with Vericiguat in VICTORIA.

Drug Interactions and Special Populations

PDE-5 Inhibitors: Concomitant use is not recommended. Lactation: Breastfeeding is not recommended 8.1 Pregnancy Pregnancy Surveillance Program There is a Pregnancy Surveillance Program that monitors pregnancy outcomes in women exposed to Vericiguat during pregnancy. Health care providers should report any prenatal exposure to Vericiguat by calling 1-877-888-4231 or at https://pregnancyreporting.Vericiguat-us.com. Risk Summary Based on data from animal reproduction studies, Vericiguat may cause fetal harm when administered to a pregnant woman and is contraindicated during pregnancy . There are no available data with Vericiguat use in pregnant women. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: VERQUVO public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.